FMC Corporation — Jul 29, 2026 release
Fiscal 2026 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000037785-26-000139
Showing in the filing
Volume
“expected to be lower”
Period
Q3 FY2026
Measure
Company-defined measure
Source
Prose
All guidance in this release · 35
Revenue excluding India (full-year) for FY2026
“a range of $3.50 billion to $3.70 billion”
Adjusted EBITDA (full-year) for FY2026
“a range of $620 million to $680 million”
Adjusted earnings per diluted share (full-ye… for FY2026
“a range of $1.19 to $1.49”
Free cash flow (full-year) for FY2026
“increased to a range of $75 million to $225 million”
Debt-reduction proceeds target for FY2026
“approximately $1 billion of proceeds”
Proceeds to be used for debt paydown
“approximately $1 billion”
Price (full-year outlook) for FY2026
“expected to be lower by mid-to-high single digits”
Volume excluding India (full-year outlook) for FY2026
“expected to be in line with prior year”
India headwind (full-year outlook) for FY2026
“a 2 percent headwind”
Revenue excluding India for Q3 FY2026
“expected to be in the range of $840 million to $900 million”
Revenue Excl. India for Q3 FY2026
“$840 million to $900 million”
Volume for Q3 FY2026
“expected to be lower”
Adjusted EBITDA for Q3 FY2026
“forecasted to be in the range of $120 million to $140 million”
Adjusted EBITDA for Q3 FY2026
“$120 million to $140 million”
Adjusted earnings per diluted share for Q3 FY2026
“in the range of $0.05 to $0.13”
Adjusted earnings per diluted share for Q3 FY2026
“$0.05 to $0.13”
Revenue excluding India for Q4 FY2026
“expected to be in the range of $1.06 billion to $1.20 billion”
Revenue Excl. India for Q4 FY2026
“$1.06 billion to $1.20 billion”
Volume for Q4 FY2026
“expected to show healthy growth”
Adjusted EBITDA for Q4 FY2026
“forecasted to be in the range of $275 million to $315 million”
Adjusted EBITDA for Q4 FY2026
“$275 million to $315 million”
Adjusted earnings per diluted share for Q4 FY2026
“in the range of $1.09 to $1.33”
Adjusted earnings per diluted share for Q4 FY2026
“$1.09 to $1.33”
Adjusted EPS for Q4 FY2026
“$1.09 to $1.33”
Revenue for FY2026
“$3.50 billion to $3.70 billion”
Revenue Excl. India for FY2026
“$3.50 billion to $3.70 billion”
Growth at midpoint vs. 2025 (Revenue Excl. I… for FY2026
“(7)%”
Growth at midpoint vs. 2025 (Revenue Excl. I… for Q3 FY2026
“(9)%”
Growth at midpoint vs. 2025 (Revenue Excl. I… for Q4 FY2026
“4%”
Growth at midpoint vs. 2025 for Q4 FY2026
“4%”
Adjusted EBITDA for FY2026
“$395 million to $455 million”
Growth at midpoint vs. 2025 for Q3 FY2026
“(45)%”
Adjusted EPS for FY2026
“$1.19 to $1.49”
Adjusted EPS for Q3 FY2026
“$0.05 to $0.13”
Diluted shares assumed for EPS estimates for Q3 FY2026
“125.9 million diluted shares”
Exhibit 99.1 · the passage around this item
… earlier in the release
4 Page 5 / FMC Corporation reports second quarter 2026 results including with Adjusted EBITDA above high end of guidance range and solid cash generation Third Quarter and Fourth Quarter Outlooks 1 Third quarter revenue excluding India is expected to be in the range of $840 million to $900 million, down 9 percent at the midpoint versus third quarter 2025. Price is expected to be lower by mid-to-high single digits. FX is expected to be neutral. Volume is expected to be lower as distributors in North America shift orders from Q3 to Q4 to align purchases more closely with application timing and manage inventory levels. Adjusted EBITDA is forecasted to be in the range of $120 million to $140 million, a decrease of 45 percent at the midpoint versus the prior year as lower sales and an FX headwind are partially offset by favorable costs. FMC expects adjusted earnings per diluted share to be in the range of $0.05 to $0.13 in the third quarter, which represents a 90 percent decline at the midpoint versus third quarter 2025 driven mainly by lower adjusted EBITDA and higher interest expense. The company expects a return to year-over-year growth in the fourth quarter. Fourth quarter revenue excluding India is expected to be in the range of $1.06 billion to $1.20 billion, an increase of 4 percent at the midpoint versus fourth quarter 2025. Volume is expected to show healthy growth driven by increased direct sales to growers in Brazil, new active ingredients and North America distributor orders that shifted from Q3 to Q4. Price is expected to decline by mid-to-high single digits. Adjusted EBITDA is forecasted to be in the range of $275 million to $315 million, an
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.